CN114727955B - 包含降脂和降血压药物的制剂 - Google Patents
包含降脂和降血压药物的制剂 Download PDFInfo
- Publication number
- CN114727955B CN114727955B CN202080081351.3A CN202080081351A CN114727955B CN 114727955 B CN114727955 B CN 114727955B CN 202080081351 A CN202080081351 A CN 202080081351A CN 114727955 B CN114727955 B CN 114727955B
- Authority
- CN
- China
- Prior art keywords
- lowering
- oral liquid
- liquid formulation
- polyoxyethylene
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title abstract description 49
- 239000008280 blood Substances 0.000 title description 15
- 210000004369 blood Anatomy 0.000 title description 15
- 239000012669 liquid formulation Substances 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims description 66
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 39
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 25
- 239000003963 antioxidant agent Substances 0.000 claims description 19
- 229960004106 citric acid Drugs 0.000 claims description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 16
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 16
- 239000005720 sucrose Substances 0.000 claims description 16
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 15
- 229960000815 ezetimibe Drugs 0.000 claims description 15
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 14
- 229960002216 methylparaben Drugs 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 14
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 14
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 14
- 239000008213 purified water Substances 0.000 claims description 13
- 241000167854 Bourreria succulenta Species 0.000 claims description 12
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 12
- 235000019693 cherries Nutrition 0.000 claims description 12
- 229960002855 simvastatin Drugs 0.000 claims description 12
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 12
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 12
- 239000010643 fennel seed oil Substances 0.000 claims description 10
- 229940049703 saccharin sodium dihydrate Drugs 0.000 claims description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 6
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 abstract description 27
- 239000003381 stabilizer Substances 0.000 abstract description 23
- 230000036772 blood pressure Effects 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 4
- 235000012000 cholesterol Nutrition 0.000 abstract description 2
- 239000000693 micelle Substances 0.000 abstract 1
- -1 prandipine Chemical compound 0.000 description 76
- 239000002904 solvent Substances 0.000 description 41
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 31
- 239000000796 flavoring agent Substances 0.000 description 27
- 239000003755 preservative agent Substances 0.000 description 26
- 235000013355 food flavoring agent Nutrition 0.000 description 25
- 235000003599 food sweetener Nutrition 0.000 description 25
- 239000003765 sweetening agent Substances 0.000 description 25
- 150000003839 salts Chemical class 0.000 description 24
- 239000000546 pharmaceutical excipient Substances 0.000 description 23
- 235000014113 dietary fatty acids Nutrition 0.000 description 22
- 239000000194 fatty acid Substances 0.000 description 22
- 229930195729 fatty acid Natural products 0.000 description 22
- 239000008186 active pharmaceutical agent Substances 0.000 description 18
- 239000006172 buffering agent Substances 0.000 description 18
- 230000003381 solubilizing effect Effects 0.000 description 17
- 239000004359 castor oil Substances 0.000 description 16
- 235000019438 castor oil Nutrition 0.000 description 16
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 235000015165 citric acid Nutrition 0.000 description 15
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 14
- 239000005541 ACE inhibitor Substances 0.000 description 13
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 13
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000002736 nonionic surfactant Substances 0.000 description 12
- 239000000600 sorbitol Substances 0.000 description 12
- 229960000528 amlodipine Drugs 0.000 description 11
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 229960002297 fenofibrate Drugs 0.000 description 10
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 10
- 229940127291 Calcium channel antagonist Drugs 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241001553178 Arachis glabrata Species 0.000 description 8
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 8
- 229940123715 Chloride channel antagonist Drugs 0.000 description 8
- 239000004599 antimicrobial Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000001747 exhibiting effect Effects 0.000 description 8
- 150000004665 fatty acids Chemical group 0.000 description 8
- CPTNXTSDQJQEFA-ZKOWQLKRSA-N mastoparan-A Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=CNC2=C1 CPTNXTSDQJQEFA-ZKOWQLKRSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 7
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 7
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 7
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 7
- 239000002083 C09CA01 - Losartan Substances 0.000 description 7
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 7
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 108010061435 Enalapril Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 7
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 7
- 239000005480 Olmesartan Substances 0.000 description 7
- 229960004530 benazepril Drugs 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 229960000830 captopril Drugs 0.000 description 7
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 7
- 229960000873 enalapril Drugs 0.000 description 7
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 229960003580 felodipine Drugs 0.000 description 7
- 229960002490 fosinopril Drugs 0.000 description 7
- 229960004427 isradipine Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229960004773 losartan Drugs 0.000 description 7
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 7
- 229960001783 nicardipine Drugs 0.000 description 7
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 7
- 229960001597 nifedipine Drugs 0.000 description 7
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 7
- 229960005117 olmesartan Drugs 0.000 description 7
- 229960001455 quinapril Drugs 0.000 description 7
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 7
- 229960003401 ramipril Drugs 0.000 description 7
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 7
- 229960005187 telmisartan Drugs 0.000 description 7
- 229960004699 valsartan Drugs 0.000 description 7
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 6
- 229960000227 nisoldipine Drugs 0.000 description 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 5
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 5
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 5
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 5
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229960005370 atorvastatin Drugs 0.000 description 5
- 229960000932 candesartan Drugs 0.000 description 5
- 229960001214 clofibrate Drugs 0.000 description 5
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 5
- 239000003349 gelling agent Substances 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- 229960002198 irbesartan Drugs 0.000 description 5
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- 244000147935 Condalia obovata Species 0.000 description 4
- 235000008317 Condalia obovata Nutrition 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- PNAMDJVUJCJOIX-IUNFJCKHSA-N [(1s,3r,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate;(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-IUNFJCKHSA-N 0.000 description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
- 229940077388 benzenesulfonate Drugs 0.000 description 4
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
- 229940050390 benzoate Drugs 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000223 polyglycerol Polymers 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000005485 Azilsartan Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 239000002160 alpha blocker Substances 0.000 description 3
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 3
- 229960002731 azilsartan Drugs 0.000 description 3
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 229960004349 candesartan cilexetil Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229960003627 gemfibrozil Drugs 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 229960000672 rosuvastatin Drugs 0.000 description 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 description 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 2
- BMOVQUBVGICXQN-UHFFFAOYSA-N Clinofibrate Chemical compound C1=CC(OC(C)(CC)C(O)=O)=CC=C1C1(C=2C=CC(OC(C)(CC)C(O)=O)=CC=2)CCCCC1 BMOVQUBVGICXQN-UHFFFAOYSA-N 0.000 description 2
- 229920002905 Colesevelam Polymers 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 239000005475 Fimasartan Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 2
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229950004646 azelnidipine Drugs 0.000 description 2
- 229960002992 barnidipine Drugs 0.000 description 2
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 2
- 229960004916 benidipine Drugs 0.000 description 2
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- 229920000080 bile acid sequestrant Polymers 0.000 description 2
- 229940096699 bile acid sequestrants Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960005025 cilazapril Drugs 0.000 description 2
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 2
- 229960002174 ciprofibrate Drugs 0.000 description 2
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 229950003072 clinofibrate Drugs 0.000 description 2
- 229960001152 colesevelam Drugs 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 229950003102 efonidipine Drugs 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 229960003489 fimasartan Drugs 0.000 description 2
- AMEROGPZOLAFBN-UHFFFAOYSA-N fimasartan Chemical compound CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 AMEROGPZOLAFBN-UHFFFAOYSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229960001195 imidapril Drugs 0.000 description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960004340 lacidipine Drugs 0.000 description 2
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229960004294 lercanidipine Drugs 0.000 description 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 229960003963 manidipine Drugs 0.000 description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229950009116 mevastatin Drugs 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- 239000012184 mineral wax Substances 0.000 description 2
- 229960005366 nilvadipine Drugs 0.000 description 2
- 229960005425 nitrendipine Drugs 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000019809 paraffin wax Nutrition 0.000 description 2
- 229960002582 perindopril Drugs 0.000 description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 229960002965 pravastatin Drugs 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 229960002051 trandolapril Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JWAZHODZSADEHB-UHFFFAOYSA-M 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate;2-hydroxyethyl(trimethyl)azanium Chemical compound C[N+](C)(C)CCO.C1=CC(OC(C)(C)C([O-])=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 JWAZHODZSADEHB-UHFFFAOYSA-M 0.000 description 1
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- LYRSLMWAHYTKIG-UHFFFAOYSA-N 3-(1h-inden-1-yl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C2C3=CC=CC=C3C=C2)=C1 LYRSLMWAHYTKIG-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 241001148717 Lygeum spartum Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002511 Poloxamer 237 Polymers 0.000 description 1
- 229920002517 Poloxamer 338 Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229940079365 atorvastatin and amlodipine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229950011350 bococizumab Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 229960003653 choline fenofibrate Drugs 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001390 poly(hydroxyalkylmethacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004058 simfibrate Drugs 0.000 description 1
- 229940074790 simvastatin and ezetimibe Drugs 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本申请公开了降脂/降胆固醇药物和降血压药物及其组合的口服液体制剂,其包含作为稳定剂(一种或多种)的表面活性剂(一种或多种),表面活性剂与药物分子形成胶团以提高它们的溶解度和稳定性。
Description
本申请要求2019年11月25日提交的美国临时专利申请序列号62/939,729的权益,其内容通过引用并入本文。
技术领域
本公开涉及用于治疗和预防高脂血症、混合型血脂异常、杂合子家族性高胆固醇血症、动脉粥样硬化性心血管疾病、高血压和/或冠状动脉疾病的口服液体制剂。
背景技术
降脂药物用于a)降低冠心病死亡率和死亡的风险,b)降低非致命性心肌梗塞和中风的风险,以及c)减少冠状动脉血运重建术的需要。降脂药物也可作为饮食的辅助来治疗高脂血症,包括降低升高的总胆固醇和甘油三酯以及高密度脂蛋白的升高。这类药物可用于治疗患有杂合子家族性高胆固醇血症的青少年患者。
几种降脂药物是市售的。这些包括:1)HMG CoA抑制剂(他汀类药物),如辛伐他汀、洛伐他汀、普伐他汀、氟伐他汀、美伐他汀、阿托伐他汀、罗苏伐他汀、匹伐他汀及其药学上可接受的盐;2)胆固醇吸收抑制剂,如依折麦布;3)胆汁酸螯合剂,如消胆胺、考来替泊和考来维仑;4)烟酸(又名尼克酸)、烟酸的酯及其药学上可接受的盐;5)苯氧酸类(fibrate)药物,如苯扎贝特、环丙贝特、克利贝特、氯贝特、氯贝胺、非诺贝特、吉非贝齐、氯烟贝特(ronifibrate)、双贝特(simfibrate)及其药学上可接受的盐;6)PCSK9抑制剂,如阿利库单抗(alirocumab)、伯考赛珠单抗(bococizumab)和依洛尤单抗(evolocumab)。这些降脂药物可单独使用或与其他降脂药物或降血压药物组合使用,用于治疗高脂血症、高血压和冠状动脉疾病。市售组合药物产品的实例包括:辛伐他汀/依折麦布和阿托伐他汀和氨氯地平(抗高血压药物)。大多数降脂药物在水性溶液中具有低的溶解度和低的稳定性,这使得它们难以在水性溶液中配制。
市售的降血压药物可分为以下几类:血管紧张素转换酶抑制剂(“ACE抑制剂”)、钙通道阻滞剂(“CCB”)、血管紧张素受体阻滞剂(“ARB”)、α-肾上腺素能阻滞剂、中枢拟交感神经药(central sympatomimetics)、利尿剂和血管扩张剂。ACE抑制剂的实例包括阿拉普利、苯那普利(benzapril)、卡托普利、西拉普利、依那普利、福辛普利、咪达普利、赖诺普利、培哚普利、喹那普利、雷米普利、群多普利、zefnopril及其药学上可接受的盐;CCB的实例包括氨氯地平、阿雷地平、阿折地平、巴尼地平、贝尼地平、克林地平(clinidipine)、地尔硫卓、依福地平、非洛地平、芬地林、戈洛帕米、伊拉地平、拉西地平、乐卡地平、马尼地平(mandipine)、尼卡地平、硝苯地平、尼伐地平、尼莫地平、尼索地平、尼群地平、prandipine、维拉帕米及其药学上可接受的盐;ARB的实例包括阿齐沙坦(azilstartan)、坎地沙坦、依普罗沙坦、非马沙坦、厄贝沙坦、氯沙坦、奥美沙坦、替米沙坦、缬沙坦及其药学上可接受的盐。α-肾上腺素能阻滞剂的实例包括多沙唑嗪、哌唑嗪、特拉唑嗪及其药学上可接受的盐。
许多降脂和降血压药物具有一些显著的配制和施用问题,例如低的溶解度和低的稳定性。尽管降脂和降血压药物代表了治疗多种人类疾病的重要化合物类别,但大多数仅以固体剂型如片剂和胶囊的形式在市场上销售。由于降脂和降血压药物的重要性,需要用于特殊患者群体的口服液体制剂,特别是无法吞咽口服固体剂型的老年病人、儿科和/或卧床不起的患者。
因此,本发明的目的是克服降脂和降血压药物的低水溶性和不稳定性挑战,和开发在治疗浓度下可溶并且在产品的整个保质期内稳定而优选不需要冷藏的口服液体制剂。
发明内容
本发明提供了降脂和/或降血压药物的稳定的口服液体制剂,其适于口服施用至人类和动物。本发明特别适用于美国药典所定义的在水中微溶、极微溶、几乎不溶或不溶的降脂和降血压药物。本发明还特别适用于在水中不稳定的降脂和降血压药物。
现已发现,通过将降脂和/或降血压药物溶解在一种或多种非水性增溶赋形剂溶液中,并将药物/非水性增溶赋形剂溶液与水混合,来获得含有在水中微溶、极微溶、几乎不溶或不溶的降脂和降血压药物降脂和/或降血压药物的稳定且治疗有效的口服液体制剂。在某些实施方式中,非水性增溶赋形剂包含一种或多种表面活性剂,优选具有脂肪酸链的一种或多种表面活性剂,更优选一种或多种非离子表面活性剂。本发明的口服液体制剂可进一步包含药学上可接受的赋形剂,例如抗氧化剂、防腐剂和/或抗微生物剂、缓冲剂/pH调节剂、甜味剂/调味剂、粘度增强剂、亲水性稳定剂及其组合。
本发明的另一方面涉及与对应的固体口服剂型例如片剂和胶囊相比具有改进的药代动力学特征的口服液体制剂。改进的药代动力学特征包括但不限于增加的吸收,即与含有相同量的降脂和/或降血压药物的类似固体口服剂型相比更高的AUC值。认为药物/非水性增溶赋形剂溶液将通过增加吸收速率和/或通过增加药物从患者或受试者的胃肠道吸收的量来增强在水中微溶、极微溶、几乎不溶或不溶的降脂和降血压药物的吸收。这种增强吸收将允许药物的较低剂量,同时获得与含有更大量药物的常规固体剂型相似的治疗或血浆水平。
本发明的另一方面涉及通过以下步骤制备如本文所述的口服液体制剂的方法,(a)将降脂和/或降血压药物溶解在一种或多种非水性增溶赋形剂中,和(b)将药物/非水性增溶赋形剂溶液与水混合。在某些实施方式中,步骤(b)的水是缓冲水性溶液。在另一个实施方式中,步骤(b)的水包含一种或多种亲水稳定剂、甜味剂/调味剂、防腐剂/抗微生物剂、粘度增强剂、缓冲剂/pH调节剂或其组合。在又进一步实施方式中,步骤(b)的水是缓冲水性溶液并且包含一种或多种另外的亲水稳定剂、甜味剂/调味剂、防腐剂/抗微生物剂、粘度增强剂、缓冲剂/pH调节剂或其组合。在仍进一步实施方式中,步骤(a)的药物/非水性增溶赋形剂溶液可以包含一种或多种另外的药学上可接受的赋形剂,例如共溶剂、甜味剂/调味剂、防腐剂/抗微生物剂、粘度增强剂或其组合。步骤(a)的药物/非水性增溶赋形剂溶液在与步骤(b)的水性溶液混合之前应该不含或基本上不含水。如本文所用,基本上不含水是指小于5%w/w、小于4%w/w、小于3%w/w、小于2%w/w、小于1%w/w或0%的水。
本发明的另一方面涉及在不添加水的情况下将降脂和/或降血压药物溶解在非水性增溶赋形剂中以形成非水性组合物。在溶解之前、之后或同时,可以添加其他非水性赋形剂,例如共溶剂、抗氧化剂、防腐剂/抗微生物剂、缓冲剂/pH调节剂、甜味剂/调味剂、粘度增强剂及其组合以形成不含或基本上不含水并且其中降脂和/或降血压药物溶解或基本上溶解的溶液或混悬液,即小于5%、小于4%、小于3%、小于2%、小于1%的药物总量未溶解。这些非水性组合物可以直接作为口服溶液服用或封装在软凝胶胶囊中并口服。在胃肠道中与水接触后,这些非水性组合物自发形成促进口服吸收的微乳液。
本发明的另一方面涉及治疗患者,特别是儿科患者的高脂血症、混合型血脂异常或杂合子家族性高胆固醇血症,或降低患有明显动脉粥样硬化性心血管疾病、高血压和/或冠状动脉疾病的患者的心血管死亡率和发病率的方法,该方法包括向需要其的受试者施用治疗有效量的根据本文公开的本发明的任何实施方式的口服液体制剂。
具体实施方式
在进一步描述本发明之前,应理解本发明不限于所描述的特定实施方式。还应理解,本文使用的术语仅出于描述特定实施方式的目的,而不是限制性的。
应当注意,如本文所用,单数形式“一个”、“一种”和“该”包括复数指示物,除非上下文另有明确规定。
在本公开中提供了多个值的范围。应当理解,除非上下文另有明确规定,也具体公开了在该范围的上限和下限之间的每个介于中间的值,到下限单位的十分之一。任何规定值或规定范围内的中间值与该规定范围内的任何其他规定或中间值之间的每个较小范围都包含在本发明内。这些较小范围的上限和下限可以独立地包括或排除在该范围内,并且其中一个、没有一个或两个限制都包括在较小范围内的每个范围也包括在本发明之内,但受制于本文中任何明确排除的限制。当规定的范围包括一个或两个限制时,排除那些包括的限制中的任何一个或两个的范围也包括在本发明中。术语“约”通常是指指定数字的正负10%。例如,“约10%”可以表示9%到11%的范围,“约20”可以表示从18到22。“约”的其他含义可以从上下文中显而易见,例如四舍五入,所以,例如“约1”也可以表示从0.5到1.4。类似地,“约0.2”可以包含值0.22。
如本文所用,术语“%w/w”表示组分在液体制剂或基于上下文提及或暗示的相关组合物的总重量中的重量百分比,这对于本领域普通技术人员来说应该是清楚的。
术语“HLB”是指表面活性剂或乳化剂的“亲水-亲油平衡”,是亲水或亲油程度的量度,并且通过计算分子的不同区域的值来确定,如Griffin WC所描述,“Calculation ofHLB Values of Non-Ionic Surfactants,"Journal of the Society of CosmeticChemists,5:259(1954)”。HLB值范围从0到20,其中HLB值为0对应于完全亲油的分子,值为20对应于完全亲水的分子。HLB值通常是已知的,并在制造商的技术手册等文献中进行了报道。
术语“微溶”、“极微溶”、“几乎不溶”和“不溶”应符合美国药典(“USP”)提供的含义。更具体地说,USP提供了下表来描述溶解度:
描述性术语 | 1份溶质需要的溶剂份数 |
极易溶 | 小于1 |
易溶 | 从1到10 |
可溶 | 从10到30 |
略溶 | 从30到100 |
微溶 | 从100到1000 |
极微溶 | 从1000到10,000 |
几乎不溶或不溶 | 大于或等于10,000 |
除非另有定义,本文使用的所有技术和科学术语与本发明所属领域的普通技术人员通常理解的含义相同。尽管与本文描述的那些相似或等效的任何方法和材料也可以用于本发明的实践或测试,但是现在描述优选的方法和材料。本文提及的所有出版物均通过引用并入本文以公开和描述与引用该出版物相关的方法和/或材料。
本发明的口服液体制剂将包含一种或多种在水中微溶、极微溶或几乎不溶的降脂和/或降血压药物。可用于本发明的在水中微溶、极微溶或几乎不溶的降脂和/或降血压药物的实例包括依折麦布、他汀类药物,如辛伐他汀、洛伐他汀、普伐他汀、氟伐他汀、美伐他汀、阿托伐他汀、罗舒伐他汀、匹伐他汀及其药学上可接受的盐;胆汁酸螯合剂,例如消胆胺、考来替泊和考来维仑;苯氧酸类药物,例如苯扎贝特、环丙贝特、克利贝特、氯贝特、氯贝胺、非诺贝特、吉非贝齐、氯烟贝特、双贝特及其药学上可接受的盐;PCSK9抑制剂,如如阿利库单抗、伯考赛珠单抗和依洛尤单抗;ACE抑制剂,如阿拉普利、苯那普利、卡托普利、西拉普利、依那普利、福辛普利、咪达普利、赖诺普利、培哚普利、喹那普利、雷米普利、群多普利、zefnopril及其药学上可接受的盐;CCB,如氨氯地平、阿雷地平、阿泽地平、巴尼地平、贝尼地平、克林地平、地尔硫卓、依福地平、非洛地平、芬地林、戈洛帕米、伊拉地平、拉西地平、乐卡地平、马尼地平、尼卡地平、硝苯地平、尼伐地平、尼莫地平、尼索地平、尼群地平、prandipine、维拉帕米及其药学上可接受的盐;ARB,如阿齐沙坦、坎地沙坦、依普罗沙坦、非马沙坦、厄贝沙坦、氯沙坦、奥美沙坦、替米沙坦、缬沙坦及其药学上可接受的盐,和α-肾上腺素能阻滞剂,如多沙唑嗪、哌唑嗪和特拉唑嗪。
在某些优选的实施方式中,本发明的口服液体制剂将包含一种或多种降脂和/或降血压药物,其在水中微溶,优选极微溶,最优选在水中几乎不溶或不溶,选择依折麦布、他汀类药物如辛伐他汀、洛伐他汀、阿托伐他汀(包括碱金属盐和碱土金属盐,如钠盐、钾盐、钙盐和镁盐)、罗舒伐他汀(包括碱金属盐和碱土金属盐,如钠盐、钾盐和镁盐),苯氧酸类药物,如氯贝特、非诺贝特、胆碱非诺贝特、吉非贝齐,ACE抑制剂如苯那普利、卡托普利、依那普利、福辛普利、喹那普利、雷米普利及其药学上可接受的盐;CCB,如氨氯地平(包括苯磺酸盐、苯甲酸盐、马来酸盐和甲磺酸盐)、非洛地平、伊拉地平、尼卡地平、硝苯地平、尼索地平及其药学上可接受的盐;ARB,如坎地沙坦、坎地沙坦西酯、厄贝沙坦、氯沙坦、奥美沙坦、替米沙坦、缬沙坦及其药学上可接受的盐和组合。
在某些实施方式中,本发明的口服液体制剂将包含:
(a)0.05%-10%w/w,优选0.1%-5%w/w,并且最优选0.15-2.5%w/w的依折麦布;
(b)0.05%-20%w/w,优选0.1%-10%w/w,并且最优选0.15%-5wt%的他汀类药物或其盐;
(c)0.05%-10%w/w,优选0.1%-5%w/w,并且最优选0.15%-2.5%w/w的非诺贝特;
(d)0.05%-20%w/w,优选0.1%-10%w/w,并且最优选0.15%-5%w/w的ACE抑制剂、CCB和/或ARB,优选ACE抑制剂、CCB和/或ARB是苯那普利、卡托普利、依那普利、福辛普利、喹那普利、雷米普利、氨氯地平(包括苯磺酸盐、苯甲酸盐、马来酸盐和甲磺酸盐)、非洛地平、伊拉地平、尼卡地平、硝苯地平、尼索地平、坎地沙坦、坎地沙坦西酯、厄贝沙坦、氯沙坦、奥美沙坦、替米沙坦、缬沙坦及其药学上可接受的盐或组合;
(e)0.05%-10%w/w,优选0.1%-5%w/w,并且最优选0.15-2.5%w/w的依折麦布结合0.05%-20%,优选0.1%-10%w/w,并且最优选0.15%-5wt%的他汀类药物或其盐;
(f)0.05%-10%w/w,优选0.1%-5%w/w,并且最优选0.15-2.5%w/w的依折麦布结合0.05%-10%w/w,优选0.1%-5%w/w的组合,并且最优选0.15%-2.5%w/w的非诺贝特;
(g)0.05%-10%w/w,优选0.1%-5%w/w,并且最优选0.15-2.5%w/w的依折麦布结合0.05%-20%w/w,优选0.1%-10%w/w的组合,最优选0.15%-5%w/w的ACE抑制剂、CCB和/或ARB,优选ACE抑制剂、CCB和/或ARB是苯那普利、卡托普利、依那普利、福辛普利、喹那普利、雷米普利、氨氯地平(包括苯磺酸盐、苯甲酸盐、马来酸盐和甲磺酸盐)、非洛地平、伊拉地平、尼卡地平、硝苯地平、尼索地平、坎地沙坦、坎地沙坦西酯、厄贝沙坦、氯沙坦、奥美沙坦、替米沙坦、缬沙坦及其药学上可接受的盐或其组合;
(h)0.05%-20%w/w,优选0.1%-10%w/w,并且最优选0.15%-5%的他汀类药物或其盐结合0.05%-20%w/w,优选0.1%-5的组合%w/w,最优选0.15%-2.5%w/w的非诺贝特;
(i)0.05%-20%w/w,优选0.1%-10%w/w,并且最优选0.15%-5%的他汀类药物或其盐结合0.05%-20%w/w,优选0.1%-10%w/w,最优选0.15%-5%w/w的ACE抑制剂、CCB和/或ARB,优选ACE抑制剂、CCB和/或ARB是苯那普利、卡托普利、依那普利、福辛普利、喹那普利、雷米普利、氨氯地平(包括苯磺酸盐、苯甲酸盐、马来酸盐和甲磺酸盐)、非洛地平、伊拉地平、尼卡地平、硝苯地平、尼索地平、坎地沙坦、坎地沙坦西酯、厄贝沙坦、氯沙坦、奥美沙坦、替米沙坦、缬沙坦及其药学上可接受的盐或其组合;或
(i)0.05%-20%w/w,优选0.1%-5%w/w,最优选0.15%-2.5%w/w的非诺贝特结合0.05%-20%w/w,优选0.1%-10%w/w,最优选0.15%-5%w/w的ACE抑制剂、CCB和/或ARB,优选ACE抑制剂、CCB和/或ARB是苯那普利、卡托普利、依那普利、福辛普利、喹那普利、雷米普利、氨氯地平(包括苯磺酸盐、苯甲酸盐、马来酸盐和甲磺酸盐)、非洛地平、伊拉地平、尼卡地平、硝苯地平、尼索地平、坎地沙坦、坎地沙坦西酯、厄贝沙坦、氯沙坦、奥美沙坦、替米沙坦、缬沙坦及其药学上可接受的盐或其组合。
本发明的口服液体制剂还可以包含一种或多种药物,其包括但不限于在水中极易溶解、易溶解、可溶和/或略溶的降脂和降血压药物,条件是口服液体制剂包含在水中微溶、极微溶或几乎不溶的一种或多种降脂和/或降血压药物。
本发明的非水性增溶赋形剂在环境条件下,即25℃和标准大气压下应为液体,并应能够溶解在水中微溶至不溶的降脂和/或降血压药物。非水性增溶赋形剂应占口服液体组合物的约10%-90%w/w,优选占口服液体组合物的约10%-80%w/w,并且最优选占口服液体组合物的10%-75%w/w。在某些实施方式中,非水性增溶赋形剂应占口服液体组合物的至少约10%、15%、20%、25%、30、35%、40%或50%w/w,并且小于口服液体组合物的90%、85%、80%、75%、70%、65%、60%、55%或50%w/w。非水溶性赋形剂可以是表面活性剂,优选包含脂肪酸部分,优选C8至C20脂肪酸部分的表面活性剂。非水性增溶赋形剂也可以是离子或非离子表面活性剂。
可以使用的非离子表面活性剂的实例包括聚乙氧基蓖麻油、聚氧乙烯烷基酯、聚乙二醇化甘油酯、山梨糖醇脂肪酸酯、甘油脂肪酸酯、脂肪酸聚甘油酯、脂肪酸醇聚乙二醇醚、乙炔二醇、乙炔醇、氧化烯嵌段聚合物、聚氧乙烯烷基醚、聚氧乙烯烷基芳基醚、聚氧乙烯苯乙烯基芳基醚、聚氧乙二醇烷基醚(polyoxyethylene glycol alkyl ether)、聚氧乙烯脂肪酸酯、聚氧乙烯山梨糖醇脂肪酸酯、聚氧乙烯甘油脂肪酸酯、聚氧乙烯氢化蓖麻油、聚氧丙烯脂肪酸酯、聚氧甘油酯、聚氧乙烯硬脂酸酯或前述的混合物。可能的非离子表面活性剂的进一步列表可见于Martindale,The Extra Pharmacopoeia,第29版第1243-1249页,其通过引用并入本文。
在某些实施方式中,非水性增溶赋形剂包含一种或多种表面活性剂,优选展现10或更大、约11或更大、约12或更大、约13或更大或约14或更大的HLB值的非离子表面活性剂。
在某些实施方式中,非水性增溶赋形剂包含一种或多种表面活性剂,优选展现小于10的HLB值,更优选约9或更小、约8或更小、约7或更小、约6或更小,或约5或更小的HLB值的非离子表面活性剂。
在某些实施方式中,非水性增溶赋形剂包含以下的混合物:(i)一种或多种表面活性剂,优选非离子表面活性剂,其展现10或更大、约11或更大、约12或更大、约13或更大或约14或更大的HLB值,和(ii)一种或多种表面活性剂,优选非离子表面活性剂,其展现小于10的HLB值,更优选约9或更小、约8或更小、约7或更小、约6或更小、或约5或更小的HLB值。一种或多种HLB值为10或更大的表面活性剂与一种或多种HLB值为小于10的表面活性剂的重量比可以为0.2:1至1:02,优选0.5:1至1:05,并且最优选0.75:1至1:0.75。
在本发明的另一个实施方式中,口服液体制剂将包含一种或多种表面活性剂,该一种或多种表面活性剂展现10或更大、约11或更大、约12或更大、约13或更大或约14或更大的HLB值,该一种或多种表面活性剂的量占口服液体制剂的总重量的10%w/w或更大,优选占组合物的总重量的约15%w/w或更大,并且最优选约20%w/w或更大。在某些实施方式中,展现10或更大的HLB值的一种或多种表面活性剂可以以如下量存在于组合物中:约10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%、21%、22%、23%、24%、25%、26%、27%、28%、29%、30%、31%、32%、33%、34%、35%、36%、37%、38%、39%、40%、41%、42%、43%、44%、45%、46%、47%、48%、49%、50%、51%、52%、53%、54%、55%、56%、57%、58%、59%、60%w/w或前述值所涵盖的任何范围。
展现出10或更大的HLB值的一种或多种表面活性剂的实例可以是非离子表面活性剂,如脂肪醇酸或酰胺乙氧基化物、甘油单酯乙氧基化物、山梨糖醇酯乙氧基化物烷基多苷,以及其混合物。这些非离子表面活性剂的实例包括但不限于多元醇酯的聚氧乙烯衍生物,如聚山梨醇酯20(以商品名20商购)、聚山梨醇酯40(以商品名/>40商购)、聚山梨醇酯60(商购以商品名/>60商购)和聚山梨醇酯80(以商品名/>80商购)。
展现出10或更大的HLB值的一种或多种表面活性剂的实例还包括聚氧乙烯蓖麻油,如聚氧乙烯蓖麻油(polyoxyl castor oil)或聚氧乙烯氢化蓖麻油或其混合物。这些表面活性剂的实例包括但不限于聚氧乙烯35蓖麻油(以商品名CREMAPHOR EL或KOLLIPHOR EL商购)、聚氧乙烯40氢化蓖麻油(以商品名CREMOPHOR RH 40商购)和聚氧乙烯60氢化蓖麻油。
展现出约10或更大的HLB值的一种或多种表面活性剂的进一步实例包括聚氧乙烯烷基醚,如聚氧乙烯十六十八烷基醚(polyoxyl cetostearyl ether)、聚氧乙烯十六烷基醚、聚氧乙烯十二烷基醚、聚氧乙烯油基醚、聚氧乙烯十八烷基醚、泰洛沙泊、泊洛沙姆,即,非离子聚氧乙烯-聚氧丙烯共聚物,如泊洛沙姆188、泊洛沙姆237、泊洛沙姆338、泊洛沙姆407、聚甘油酯的脂肪酸酯或脂肪酸醇,如辛酸/癸酸甘油三酯(以商品名MYIGLYOL商购)或其组合。
在本发明的某些实施方式中,口服液体剂型可包含一种或多种表面活性剂,其展现约小于10的HLB值,更优选约9或更小、约8或更小的HLB值,并且最优选约7或更小的HLB值。HLB值小于10的一种或多种表面活性剂的实例包括但不限于聚乙氧基蓖麻油、聚氧乙烯烷基酯、聚乙二醇化甘油酯、山梨糖醇脂肪酸酯、甘油脂肪酸酯、脂肪酸聚甘油酯、脂肪酸醇聚乙二醇醚、乙炔二醇、乙炔醇、氧化烯嵌段聚合物、聚氧乙烯烷基醚、聚氧乙烯烷基芳基醚、聚氧乙烯苯乙烯基芳基醚、聚氧乙二醇烷基醚、聚氧乙烯脂肪酸酯、聚氧乙烯山梨糖醇脂肪酸酯、聚氧乙烯甘油脂肪酸酯、聚氧乙烯氢化蓖麻油、聚氧丙烯脂肪酸酯或前述的混合物。具有低HLB值的可能的非离子表面活性剂的进一步列表可见于Martindale,The ExtraPharmacopoeia,第29版第1243-1249页,其通过引用并入本文。
在某些实施方式中,HLB值小于10的一种或多种表面活性剂可以包含中链(即,约4至约20个碳原子,优选约6至约18个碳原子,并且最优选约6至约14个碳原子)甘油单酯或甘油二酯,如辛酸/癸酸甘油酯(以商品名CAPMUL MCM商购)、辛酸甘油酯(以商品名CAPMULMCM C8商购)、癸酸甘油酯(以商品名CAPMUL MCM C10商购)、单辛癸酸甘油酯(glycerylmonocaprylocaprate)(以商品名CAPMUL 471商购)或其混合物。
在某些实施方式中,具有小于10的HLB值的一种或多种表面活性剂可以包括聚氧甘油酯,例如辛基己酰聚氧甘油酯(caprylocaproyl polyoxylglycerides)月桂酰聚氧甘油酯、亚油酰聚氧甘油酯、油酰聚氧甘油酯、硬脂酰聚氧甘油酯和前述的混合物。
在某些实施方式中,HLB值小于10的一种或多种表面活性剂是山梨糖醇酯或山梨糖醇脂肪酸酯,例如山梨糖醇单月桂酸酯、山梨糖醇单油酸酯、山梨糖醇单棕榈酸酯、山梨糖醇单硬脂酸酯、山梨糖醇倍半油酸酯、山梨糖醇三油酸酯、泰洛沙泊以及前述的混合物。
在某些实施方式中,HLB值小于10的一种或多种表面活性剂是磷脂或卵磷脂。
在实施方式中,HLB值约小于10的一种或多种表面活性剂的量可以基于口服液体制剂的总重量以10%w/w或更大的量,优选基于口服液体制剂的总重量以约15%w/w或更大的量,并且最优选以约20wt%或更大的量存在于口服液体剂型中。在某些实施方式中,展现约10或更大的HLB值的一种或多种表面活性剂可以以如下量存在于组合物中:约10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%、21%、22%、23%、24%、25%、26%、27%、28%、29%、30%、31%、32%、33%、34%、35%、36%、37%、38%、39%、40%、41%、42%、43%、44%、45%、46%、47%、48%、49%、50%、51%、52%、53%、54%、55%、56%、57%、58%、59%、60%w/w或更大或由前述值涵盖的任何范围。
在某些实施方式中,非水性增溶赋形剂可进一步包含共溶剂。共溶剂的实例包括油,例如玉米油、芝麻油、棉籽油、花生油等,低分子量多元醇例如甘油、丙二醇、在环境条件下为液体的聚乙二醇(PEG),例如PEG 200、PEG 300、PEG400和PEG 600、C1-C6直链和支链一元醇,例如乙醇和苯甲醇。如果存在共溶剂,其应占口服液体制剂的约0.05%-10%w/w,优选约0.1%-7.5%w/w,并且最优选约0.5%-5%w/w。
本发明的口服液体制剂还可包含一种或多种已知的药学上可接受的赋形剂,例如抗氧化剂、防腐剂和/或抗微生物剂、缓冲剂/pH调节剂、甜味剂/调味剂、粘度增强剂、亲水稳定剂及其组合。
可用于本发明的抗氧化剂的实例包括但不限于抗坏血酸、抗坏血酸棕榈酸酯(AP)、丁基化羟基茴香醚(BHA)、丁基羟基甲苯(BHT)、柠檬酸、油酸乙酯、富马酸、次磷酸、苹果酸、单硫代甘油、焦亚硫酸钾、没食子酸丙酯、亚硫酸氢钠、甲醛次硫酸钠、焦亚硫酸钠、亚硫酸钠、硫代硫酸钠、二氧化硫、生育酚、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、对羟基苯甲酸丙酯、对羟基苯甲酸丁酯、苯甲酸苄酯、吡哆醇、乙基香草醛和其混合物。根据本发明使用的优选抗氧化剂包括BHT、BHA、AP、没食子酸丙酯、α生育酚或其任何混合物。通常,存在于本发明的组合物中的抗氧化剂的量将占组合物的总重量的约0.0001%w/w至约5%w/w,优选约0.001%w/w至约2%w/w,并且最优选约0.01%w/w至约1%w/w。
可用于本发明的缓冲剂或缓冲剂的实例包括但不限于乙酸、己二酸、碳酸铵、磷酸铵、硼酸、柠檬酸、乳酸、磷酸、柠檬酸钾、磷酸钾、乙酸钠、柠檬酸钠、碳酸钠、碳酸钾、碳酸氢钠、碳酸氢钾、乳酸钠、磷酸钠、琥珀酸及其组合。通常,缓冲剂将包含前述的组合以形成缓冲系统,例如柠檬酸和柠檬酸钠,或乙酸和乙酸钠。
可用于本发明的pH调节剂的实例包括但不限于用于调节药物组合物的pH的任何药学上可接受的酸或碱。通常用于调节药物组合物的pH的化合物的实例包括盐酸、柠檬酸、乳酸、酒石酸、冰醋酸、氢氧化钠、氢氧化钾、精氨酸、赖氨酸、葡甲胺、三乙醇胺或其组合。
如果使用,缓冲剂/pH调节剂可以占组合物的约0.01%w/w至约20%w/w,优选占组合物的约0.05%w/w至约10%w/w,最优选占组合物的约0.1%w/w至约5%w/w。在某些实施方式中,存在于口服液体制剂中的缓冲剂/pH调节剂的量应当足以在储存期间产生和维持口服液体制剂的约3-8,优选约4-7,并且最优选约4-5、5-6或6-7的pH。口服液体剂型在正常储存条件下应当保持该pH至少6个月、9个月、12个月、18个月或24个月。
如本文所用的亲水性稳定剂包括亲水性赋形剂,其能够与水分子形成氢键以降低水活度,进而稳定降脂和/或降血压药物以抵抗水解。合适的亲水性稳定剂的实例包括但不限于山梨糖醇、蔗糖、乳糖、淀粉、右旋糖、蔗糖、果糖、麦芽糖、甘露糖醇、木糖醇及其组合。如果使用亲水性稳定剂,其在口服液体制剂中的含量应为约0.01%-30%w/w,优选0.05%-20%w/w,并且最优选含有0.1%-10%w/w。
可用于本发明的粘度增强剂包括有机材料,例如天然或合成蜡、C12-C60醇、C12-C60酸、α-羟基脂肪酸、多羟基脂肪酸酯、多羟基脂肪酸酰胺,和无机/有机材料,例如含有锌、钙、铝或镁的金属酯络合物、气相二氧化硅和有机粘土。另外的粘度增强剂包括多元醇聚酯、甘油酯、聚甘油酯和聚硅氧烷。
蜡也适合用作本发明的组合物中的粘度增强剂。天然蜡可包括但不限于巴西棕榈蜡、地蜡(ozokerite)、蜂蜡、小烛树蜡、石蜡、矿蜡(ceresin)、细茎针草(esparto)、小冠椰子(ouricuri)、rezowax和其他已知的开采的蜡和矿物蜡。合成蜡可以包括但不限于石蜡和微晶蜡。
可包含在本发明的组合物中的更进一步的粘度增强剂是胶凝剂。胶凝剂是与水接触时会膨胀或扩张的材料。可用于本发明的胶凝剂的实例包括可溶胀聚合物,也称为渗透聚合物或水凝胶。可溶胀聚合物可以是非交联的或轻度交联的。交联可以与具有在流体存在下溶胀能力的聚合物形成共价键或离子键,并且当交联时,其不会溶解在流体中。聚合物可以是植物、动物或合成来源的。可用于本发明目的的聚合物胶凝剂包括分子量大于50,000的聚羟烷基纤维素,例如羟丙基甲基纤维素(METHOCEL K 100M,获得自Dow Chemical);分子量为5,000至5,000,000的聚(羟烷基甲基丙烯酸酯);分子量为100,000至3,000,000的聚(乙烯基吡咯烷酮);阴离子和阳离子水凝胶;聚(电解质)络合物;具有低乙酸残留的聚(乙烯醇);琼脂和羧甲基纤维素的可溶胀混合物;包含混合有少量交联琼脂的甲基纤维素的可溶胀组合物;分子量为10,000至6,000,000的聚醚;由马来酸酐与苯乙烯、乙烯、丙烯或异丁烯的精细分散共聚物的分散体产生的水溶胀性共聚物;N-乙烯基内酰胺的水溶胀性聚合物等。
可用于本发明的其他胶凝剂包括分子量范围为30,000至300,000的果胶;多糖类,如琼脂、金合欢胶、梧桐树胶、黄蓍胶、藻胶和瓜尔胶;一种丙烯酸聚合物,一种羧基乙烯基聚合物,有时也称为羧基聚亚甲基,一种丙烯酸与蔗糖的聚烯丙基醚交联的聚合物,如美国专利号2,798,053和2,909,462所述,并且可作为/>934、940和941及其盐衍生物获得;聚丙烯酰胺;水溶胀性茚马来酸酐聚合物;GOOD/>聚丙烯酸,分子量为80,000至200,000;POLYOXTM聚环氧乙烷聚合物,分子量为100,000至7,000,000;淀粉接枝共聚物;AQUA-KEEPTM丙烯酸酯聚合物,其吸水性约为其原始重量的400倍;聚葡聚糖的二酯;交联聚乙烯醇和聚(N-乙烯基-2-吡咯烷酮)的混合物;聚乙二醇,分子量为4,000至100,000。具有胶凝性质的代表性聚合物描述于美国专利号6,419,954、4,915,949、4,327,725、4,207,893,和由Cleveland Rubber Company,Cleveland,Ohio出版的Scott和Roff编写的常见聚合物手册(Handbook of Common Polymers)。
粘度增强剂的其他实例包括阿拉伯胶、聚维酮、羟丙甲纤维素、羟丙基纤维素、羟乙基纤维素、聚环氧乙烷、聚甲基丙烯酸酯、甲基纤维素、乙基纤维素、预糊化淀粉、明胶、黄蓍胶、玉米醇溶蛋白或其混合物。在某些实施方式中,粘度增强剂是水溶性的,例如聚维酮、羟丙甲纤维素、羟丙基纤维素、明胶及其混合物。
通常,存在于本发明的组合物中的粘度增强剂的量将占组合物的总重量的约0%w/w至约10%w/w,优选约0.01%w/w至约5%w/w,并且最优选约0.05%w/w至约3%w/w。
可用于本发明的固体剂型的甜味剂/调味剂的实例包括天然和人造甜味剂,例如蔗糖、阿斯巴甜、糖精、甘草酸二钾、甜叶菊、奇异果甜蛋白及其组合。可使用的调味剂包括柠檬酸、薄荷(mint)、留兰香、薄荷油(peppermint)、冬青、茴香、核桃、杏仁、薄荷醇、柠檬、酸橙、橘子、葡萄、樱桃、覆盆子、泡泡糖、巧克力和香草提取物或油及其组合。在美国专利号6,027,746中描述了另外的口味增强剂,其通过引用并入本文。存在于口服液体制剂中的甜味剂/调味剂的量根据特定的味道特征而变化,但应当以赋予可接受的口味特征的量存在。
可用于本发明的口服液体制剂的防腐剂和/或抗微生物剂的实例包括苯扎氯铵、苄索氯铵、苯甲酸、苯甲醇、对羟基苯甲酸丁酯、西曲溴铵、氯化十六烷基吡啶鎓、氯丁醇、氯甲酚、对羟基苯甲酸乙酯、对羟基苯甲酸甲酯、苯酚、苯氧乙醇、苯乙醇、苯甲酸钾、山梨酸钾、对羟基苯甲酸丙酯、苯甲酸钠、脱氢乙酸钠、丙酸钠、山梨酸、硫柳汞、百里酚及其组合。一种或多种防腐剂和/或抗微生物剂可以以口服液体制剂的约0.001%w/w至约5%w/w,优选以口服液体制剂的约0.005%w/w至约2.5%w/w,并且最优选以口服液体制剂的约0.01%w/w至约1.0%w/w的量存在于本发明的口服液体制剂中。
本发明的口服液体制剂在标准储存条件或加速条件下是稳定的。制剂中杂质的总量可以不超过约0.1至3%,标准储存条件可以包括约20至25℃(即室温)的温度并且不超过约40%的相对湿度(RH)。在一个实施方式中,本文公开的制剂在室温下稳定18至24个月或更长时间。根据本公开的制剂的稳定性可以例如通过测量制剂的物理状态(包括pH)、任何变色的存在和化学稳定性来确定,化学稳定性通过测量药物和相关化合物(例如降解产物或原料药的已知杂质)的试验来测定。
在一些实施方式中,本公开的口服液体制剂在经受预定条件持续预定时间时是稳定的。例如,本公开的口服液体制剂可以在各种预定温度和相对湿度下储存持续限定或预定时间段,例如储存在具有常规儿童安全螺帽和带或不带压入式瓶适配器/带内浸管的孔减压器的封闭的单剂量或多剂量透明或琥珀色玻璃瓶中。在一些实施方式中,本公开的制剂在受控室温(CRT)(25℃/60%RH)下(即不需要冷藏)储存长达3个月时是稳定的,并且其表现出良好的稳定性,由此药物储存期间的分析值保持在初始药物分析的98%或更大。下表显示了在CRT储存1、2、3、4、5、6、7、8、9、10、11、12个月或更长时间的口服液体制剂的稳定性值:
含有在水中微溶、极微溶、实际上不溶或不溶的降脂和/或降血压药物的口服液体制剂的以下实施例本质上是说明性的并且不旨在以任何方式进行限制。
实施例
实施例1-依折麦布和辛伐他汀的口服溶液的制备
通过将9g对羟基苯甲酸甲酯(Spectrum Chemicals)、1g对羟基苯甲酸丙酯(Spectrum Chemicals)和1g丁基化羟基茴香醚(Sigma-Aldrich)溶解在100ml丙二醇(BioWorld)中制成储备溶液来制备防腐剂-抗氧化剂溶液。接下来,通过将2.24g柠檬酸钠二水合物(Sigma-Aldrich)和1.44g柠檬酸(TCI)溶解在50ml纯化水中来制备0.3M柠檬酸盐缓冲液,并用2M HCl(Spectrum Chemicals)将pH值调节至3.06。为了制备6ml制剂,将4.331g labrasol(Gattefosse)、128mg防腐剂-抗氧化溶液、48.2mg辛伐他汀(AstraTech)、12.4mg依折麦布(Ark Pharma)、62.5mg茴香油香料(LorAnn Oils)和61.5mg樱桃油香料(Spectrum Chemical)混合在一起以形成粉红色溶液(溶液I)。接下来,将60.1mg蔗糖(Sigma Chemicals)、60.8mg糖精钠(Spectrum Chemicals)、627.6mg储备柠檬酸盐缓冲液和912mg纯化水混合在一起以形成透明溶液(溶液II)。将溶液I和溶液II混合在一起形成最终的透明粉红色液体制剂。制剂中辛伐他汀和依折麦布的最终浓度分别为8mg/ml和2mg/ml。
实施例1中概述的程序用于制备实施例2-10。
实施例2
组分 | 量(%w/w) | 功能 |
依折麦布 | 0.2 | API |
辛伐他汀 | 0.8 | API |
labrasol | 69 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.29 | 缓冲剂 |
茴香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水QS AD | 25 | 溶剂 |
实施例3
组分 | 量(%w/w) | 功能 |
依折麦布 | 0.2 | API |
辛伐他汀 | 1.6 | API |
聚山梨醇酯20 | 42.4 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.2g | 缓冲剂 |
茴香油 | 1.0 | |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | |
纯化水QS AD | 48.8 | 溶剂 |
实施例4
组分 | 量(%w/w) | 功能 |
依折麦布 | 0.2 | API |
辛伐他汀 | 1.6 | API |
聚氧乙烯35蓖麻油 | 42.4 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.29 | 缓冲剂 |
茴香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水QS AD | 48.8 | 溶剂 |
实施例5
组分 | 量(%w/w) | 功能 |
依折麦布 | 0.2 | API |
辛伐他汀 | 1.6 | API |
聚氧乙烯35蓖麻油 | 21.2 | 稳定剂/增溶剂 |
Labrasol | 21.2 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.29 | 缓冲剂 |
茴香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水QS AD | 48.8 | 溶剂 |
实施例6
组分 | 量(%w/w) | 功能 |
氨氯地平 | 0.1 | API |
辛伐他汀 | 0.8 | API |
Labrasol | 22.5 | 稳定剂/增溶剂 |
聚氧乙烯35蓖麻油 | 22.5 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
无水乙醇 | 2.6 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.2g | 缓冲剂 |
面香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水QS AD | 44.5 | 溶剂 |
实施例7
组分 | 量(%w/w) | 功能 |
氨氯地平 | 0.1 | API |
非诺贝特 | 1.6 | API |
Labrasol | 22.5 | 稳定剂/增溶剂 |
聚氧乙烯35蓖麻油 | 22.5 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
无水乙醇 | 2.6 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.29 | 缓冲剂 |
茴香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水QS AD | 43.7 | 溶剂 |
实施例8
组分 | 量(%w/w) | 功能 |
氨氯地平 | 0.1 | API |
阿托伐他汀 | 0.8 | API |
Labrasol | 22.5 | 稳定剂/增溶剂 |
聚氧乙烯35蓖麻油 | 22.5 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
无水乙醇 | 2.6 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.29 | 缓冲剂 |
茴香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水QS AD | 44.5 | 溶剂 |
实施例9
组分 | 量(%w/w) | 功能 |
非诺贝特 | 1.6 | API |
Labrasol | 22.5 | 稳定剂/增溶剂 |
聚氧乙烯35蓖麻油 | 22.5 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
无水乙醇 | 2.6 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.29 | 缓冲剂 |
茴香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水Qs AD | 43.8 | 溶剂 |
实施例10
组分 | 量(%w/w) | 功能 |
阿托伐他汀 | 1.6 | API |
非诺贝特 | 1.6 | API |
Labrasol | 22.5 | 稳定剂/增溶剂 |
聚氧乙烯35蓖麻油 | 22.5 | 稳定剂/增溶剂 |
丙二醇 | 2.0 | 增溶剂 |
无水乙醇 | 2.6 | 增溶剂 |
对羟基苯甲酸甲酯 | 0.18 | 防腐剂 |
对羟基苯甲酸丙酯 | 0.02 | 防腐剂 |
丁基化羟基茴香醚(BHA) | 0.02 | 抗氧化剂 |
柠檬酸钠二水合物 | 0.45 | 缓冲剂 |
柠檬酸 | 0.29 | 缓冲剂 |
茴香油 | 1.0 | 调味剂 |
樱桃油 | 1.0 | 调味剂 |
蔗糖 | 1.0 | 甜味剂 |
糖精钠二水合物 | 1.0 | 甜味剂 |
纯化水QS AD | 42.0 | 溶剂 |
实施例11-依折麦布和辛伐他汀的口服制剂在环境温度下的稳定性研究。
液体制剂在环境室温下储存在密封的4盎司透明玻璃瓶中;并在适当的时间间隔抽取样品进行HPLC分析、pH测量和物理观察。下表1中提供了稳定性汇总数据:
表1.在环境温度条件下储存后的稳定性数据(23-25℃)
*CPC表示无可见颗粒的透明粉红色。
以下方法用于评价制剂:
依折麦布和辛伐他汀的HPLC检测方法
HPLC色谱柱为Phenomenex Luna C18(2),5um,4.6mm×250mm。流动相由流动相A(MP-A):去离子水/甲醇2:1(v/v)和流动相B:乙腈(MP-B)组成。使用以下流动相(MP)流动程序:0-7分钟,55%的MP-A;7-8分钟,55%至30%的MP-A;8-21分钟,30%的MP-A;21-21.5分钟,30-55%的MP-A。流速为1mL/min,柱温设置为35℃。
pH测量和物理观察
用pH 4.00和pH 7.00标准校准pH计,得到>97%的斜率。校准后测量口服液体制剂的pH值。在白色/黑色背景下的室内光下观察口服液体制剂。
此外,还测量了实施例2的液体制剂在纯化水中的分散性及其液滴尺寸和ζ电位,表明该制剂易于再分散在水中,并且平均液滴尺寸为99.2+/-3.8nm,ζ电位为-12.2+/-1.4mV。
以下方法可用于评估包含阿托伐他汀、非诺贝特和氨氯地平的口服制剂。
HPLC色谱柱为Phenomenex Luna C18(2),5um,4.6mm×250mm。流动相由流动相A(MP-A):0.2%v/v磷酸,用1M NaOH调节pH至4.0;和流动相B:乙腈/甲醇1:1(v/v)(MP-B)组成。使用以下流动相(MP)流动程序:0-7分钟,47%的MP-A;7-11分钟,47%至20%的MP-A;11-22分钟,20%的MP-A;22-22.5分钟,20-47%的MP-A。流速和柱温分别设置为1mL/min和35℃。
本文示例性描述的本发明可以在缺乏本文未具体公开的任何一个或多个元素、限制的情况下实施。因此,例如,在本文的每个实例中,任何术语“包括”、“基本上由……组成”和“由……组成”都可以用其他两个术语中的任何一个来替换。已使用的术语和表达被用作描述性术语而不是限制性术语,并且在使用这些术语和表达时不旨在排除所显示和描述的特征或其部分的任何等同物,但应认识到可以在要求保护的本发明的范围内进行各种修改。因此,应当理解,虽然已经通过优选实施方式和任选的特征具体公开了本发明,但是本领域技术人员可以对本文公开的概念进行修改和变化,并且这种修改和变化被认为是在权利要求限定的本发明的范围内。
Claims (4)
1.一种口服液体制剂,其包含如下组分:
依折麦布0.1-2.5%w/w,辛伐他汀0.15-5%w/w,labrasol 50-80%w/w,丙二醇0.5-5%w/w,抗氧化剂0.01-2%w/w,柠檬酸钠二水合物和柠檬酸0.1-5%w/w,蔗糖0.1-10%w/w;所述抗氧化剂为对羟基苯甲酸甲酯、对羟基苯甲酸丙酯和丁基化羟基茴香醚的混合物。
2.根据权利要求1所述的口服液体制剂,其包含如下组分:
依折麦布0.2%w/w,辛伐他汀0.8%w/w,labrasol 69%w/w,丙二醇2.0%w/w,对羟基苯甲酸甲酯0.18%w/w,对羟基苯甲酸丙酯0.02%w/w,丁基化羟基茴香醚0.02%w/w,柠檬酸钠二水合物0.45%w/w,柠檬酸0.29%w/w,茴香油1.0%w/w,樱桃油1.0%w/w,蔗糖1.0%w/w,糖精钠二水合物1.0%w/w,纯化水25%w/w。
3.权利要求1至2中任一项所述的口服液体制剂具有在制备用于治疗高脂血症、混合型血脂异常、杂合子家族性高胆固醇血症或动脉粥样硬化性心血管疾病的治疗剂中的用途。
4.权利要求1至2中任一项所述的口服液体制剂具有在制备用于治疗高脂血症、混合型血脂异常、杂合子家族性高胆固醇血症、动脉粥样硬化性心血管疾病、高血压或冠状动脉疾病的治疗剂中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962939729P | 2019-11-25 | 2019-11-25 | |
US62/939,729 | 2019-11-25 | ||
PCT/US2020/061911 WO2021108343A1 (en) | 2019-11-25 | 2020-11-24 | Formulations comprising lipid-lowering and blood pressure-lowering drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114727955A CN114727955A (zh) | 2022-07-08 |
CN114727955B true CN114727955B (zh) | 2024-03-26 |
Family
ID=76128942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080081351.3A Active CN114727955B (zh) | 2019-11-25 | 2020-11-24 | 包含降脂和降血压药物的制剂 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240091147A1 (zh) |
CN (1) | CN114727955B (zh) |
WO (1) | WO2021108343A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11224572B1 (en) * | 2020-08-17 | 2022-01-18 | Novitium Pharma LLC | Stable oral liquid composition of terazosin |
WO2023235541A1 (en) * | 2022-06-03 | 2023-12-07 | Polaryx Therapeutics, Inc. | Gemfibrozil formulation |
CN115887393B (zh) * | 2022-10-31 | 2024-05-24 | 修正药业集团股份有限公司 | 一种奥美沙坦酯片及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1268054A (zh) * | 1997-08-29 | 2000-09-27 | 辉瑞产品公司 | 包含氨氯地平和抑制素化合物的联合疗法 |
JP2009256216A (ja) * | 2008-04-14 | 2009-11-05 | Towa Yakuhin Kk | 溶液状態で安定なアムロジピンベシル酸塩内服用液剤 |
WO2010098906A1 (en) * | 2009-02-24 | 2010-09-02 | Madeira Therapeutics | Liquid statin formulations |
CN109069651A (zh) * | 2016-04-13 | 2018-12-21 | 诺迪克控股公司 | 稳定的尼莫地平肠胃外制剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8574619B2 (en) * | 2008-09-05 | 2013-11-05 | Quercegen Pharmaceuticals, LLC | Reducing cholesterol levels with combined use of quercetin and statin |
CN102349909A (zh) * | 2011-08-19 | 2012-02-15 | 北京阜康仁生物制药科技有限公司 | 一种用于降低血脂的药物组合物 |
-
2020
- 2020-11-24 US US17/768,049 patent/US20240091147A1/en active Pending
- 2020-11-24 CN CN202080081351.3A patent/CN114727955B/zh active Active
- 2020-11-24 WO PCT/US2020/061911 patent/WO2021108343A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1268054A (zh) * | 1997-08-29 | 2000-09-27 | 辉瑞产品公司 | 包含氨氯地平和抑制素化合物的联合疗法 |
JP2009256216A (ja) * | 2008-04-14 | 2009-11-05 | Towa Yakuhin Kk | 溶液状態で安定なアムロジピンベシル酸塩内服用液剤 |
WO2010098906A1 (en) * | 2009-02-24 | 2010-09-02 | Madeira Therapeutics | Liquid statin formulations |
CN109069651A (zh) * | 2016-04-13 | 2018-12-21 | 诺迪克控股公司 | 稳定的尼莫地平肠胃外制剂 |
Also Published As
Publication number | Publication date |
---|---|
WO2021108343A1 (en) | 2021-06-03 |
US20240091147A1 (en) | 2024-03-21 |
CN114727955A (zh) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114727955B (zh) | 包含降脂和降血压药物的制剂 | |
US20140314847A1 (en) | Controlled release pharmaceutical compositions with improved bioavailabililty | |
KR101055412B1 (ko) | 두타스테라이드를 포함하는 자가유화 에멀젼 조성물 및 이의 제조방법 | |
US20090099151A1 (en) | Modified Release Pharmaceutical Compositions and Processes Thereof | |
US20170027931A1 (en) | Posaconazole pharmaceutical compositions and preparation methods, uses and pharmaceutical formulations thereof | |
US20100035886A1 (en) | Parenteral formulations of dopamine agonists | |
US20090281136A1 (en) | Prasugrel pharmaceutical formulations | |
JP2011516613A (ja) | 好ましくはポサコナゾールおよびhpmcasを含む固体分散物中の経口用薬学的組成物 | |
ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
EP2106789A1 (en) | Pharmaceutical composition comprising candesartan | |
US20240091223A1 (en) | Pharmaceutical composition comprising a diphenylpyrazine derivative | |
BRPI0620790A2 (pt) | formulação complexa que compreende cansilato de amlodipina e sinvastatina e método para a sua preparação | |
WO2014090386A1 (en) | Orally disintegrating tablet containing asenapine | |
KR101725462B1 (ko) | 칼슘 길항약/안지오텐신 ii 수용체 길항약 함유 의약 제제 | |
AU2017203605B2 (en) | Parenteral formulations of dopamine agonists | |
US20140051733A1 (en) | Febuxostat pharmaceutical compositions | |
US20200289523A1 (en) | Fixed dosed pharmaceutical composition comprising amiodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension | |
WO2024017964A1 (en) | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative | |
EP2600839B1 (en) | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cylohexane-1,1'-pyrano[3,4,b]indol]-4-amine | |
RU2628538C2 (ru) | Композиция, включающая амлодипин и лозартан, имеющая улучшенную стабильность | |
EP2839829A1 (en) | Sustained release tablet containing levodropropizine and method for preparing same | |
KR102301743B1 (ko) | 에피나코나졸 경구용 조성물 | |
US20190030006A1 (en) | Surfactant-free hiv protease inhibitor composition and method of manufacturing thereof | |
EP1906931B1 (en) | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof | |
EP2805714B1 (en) | Stable pharmaceutical composition comprising amorphous rosuvastatin calcium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |